These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 12115071)
21. Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Zannettino AC; Farrugia AN; Kortesidis A; Manavis J; To LB; Martin SK; Diamond P; Tamamura H; Lapidot T; Fujii N; Gronthos S Cancer Res; 2005 Mar; 65(5):1700-9. PubMed ID: 15753365 [TBL] [Abstract][Full Text] [Related]
22. The role of markers of bone remodeling in multiple myeloma. Terpos E; Politou M; Rahemtulla A Blood Rev; 2005 May; 19(3):125-42. PubMed ID: 15748961 [TBL] [Abstract][Full Text] [Related]
23. [Bone and myeloma]. Ravaud P; Roux C Rev Prat; 1993 Feb; 43(3):293-7. PubMed ID: 8502958 [TBL] [Abstract][Full Text] [Related]
24. Myeloma bone disease. Berenson JR Best Pract Res Clin Haematol; 2005; 18(4):653-72. PubMed ID: 16026743 [TBL] [Abstract][Full Text] [Related]
25. Effectiveness and cost of bisphosphonate therapy in tumor bone disease. Body JJ Cancer; 2003 Feb; 97(3 Suppl):859-65. PubMed ID: 12548587 [TBL] [Abstract][Full Text] [Related]
26. Maxilla osseus sequestre and oral exposure: effects of the treatment of multiple myeloma with bisphosphonates. Lobato JV; Rodrigues JM; Cavaleiro MV; Lobato JM; Xavier L; Santos JD; Maurício AC Acta Med Port; 2007; 20(2):185-92. PubMed ID: 17868526 [TBL] [Abstract][Full Text] [Related]
27. [Bone changes in multiple myeloma--current etiopathogenic, diagnostic and therapeutic aspects]. Sakalová A; Mistrík M; Gazová S; Chabronová I; Hrubisko M; Skultétyová D; Mociková H Vnitr Lek; 2002 Jul; 48(7):642-8. PubMed ID: 12197408 [TBL] [Abstract][Full Text] [Related]
29. Serum pleiotrophin levels are elevated in multiple myeloma patients and correlate with disease status. Yeh HS; Chen H; Manyak SJ; Swift RA; Campbell RA; Wang C; Li M; Lee HJ; Waterman G; Gordon MS; Ma J; Bonavida B; Berenson JR Br J Haematol; 2006 Jun; 133(5):526-9. PubMed ID: 16681640 [TBL] [Abstract][Full Text] [Related]
30. [Bone lesions in patients with multiple myeloma]. Umeda M; Takata M; Tsubuku M Nihon Naika Gakkai Zasshi; 1995 Jul; 84(7):1070-4. PubMed ID: 7561360 [No Abstract] [Full Text] [Related]
31. Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. Heider U; Kaiser M; Müller C; Jakob C; Zavrski I; Schulz CO; Fleissner C; Hecht M; Sezer O Eur J Haematol; 2006 Sep; 77(3):233-8. PubMed ID: 16923110 [TBL] [Abstract][Full Text] [Related]
32. Supportive care in multiple myeloma. Ludwig H; Zojer N Best Pract Res Clin Haematol; 2007 Dec; 20(4):817-35. PubMed ID: 18070721 [TBL] [Abstract][Full Text] [Related]
33. Relationship between serum levels of vascular endothelial growth factor, hepatocyte growth factor and matrix metalloproteinase-9 with biochemical markers of bone disease in multiple myeloma. Alexandrakis MG; Sfiridaki A; Miyakis S; Pappa C; Kandidaki E; Alegakis A; Margioris AN Clin Chim Acta; 2007 Apr; 379(1-2):31-5. PubMed ID: 17234170 [TBL] [Abstract][Full Text] [Related]
34. Myeloma and bone disease: "the dangerous tango". Epstein J; Walker R Clin Adv Hematol Oncol; 2006 Apr; 4(4):300-6. PubMed ID: 16728940 [TBL] [Abstract][Full Text] [Related]
35. [Multiple myeloma -- case report]. Zettl F; Jung W; Schroers R Dtsch Med Wochenschr; 2005 Feb; 130(6):277; quiz 287-90. PubMed ID: 15692901 [No Abstract] [Full Text] [Related]
36. [Osteonecrosis of the jaw in the course of multiple myeloma treatment and bisphosphonate administration]. Adam Z; Kozumpliková M; Pour L; Machálka M Vnitr Lek; 2006 Feb; 52(2):176-80. PubMed ID: 16623282 [TBL] [Abstract][Full Text] [Related]
37. Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease. Croucher PI; Shipman CM; Van Camp B; Vanderkerken K Cancer; 2003 Feb; 97(3 Suppl):818-24. PubMed ID: 12548581 [TBL] [Abstract][Full Text] [Related]